Evidence map›Paper›PMID 36513625›Full record

ArticleAmerican journal of medical genetics. Part A2023

A diagnosis of Birt-Hogg-Dubé syndrome in individuals with Smith-Magenis syndrome: Recommendation for cancer screening.

Cathy D Vocke, Leah R Fleming, Anna M Piskorski, Ali Amin, Chanika Phornphutkul, Suzanne de la Monte, Thierry Vilboux, Folami Duncan, Joan Pellegrino, Bonnie Braddock and 7 more

Open access · greenAbstract read
In one paragraph

Article in American journal of medical genetics. Part A, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Deletion ofJournal of genetics · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Cathy D VockeUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Leah R FlemingOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.ORCID 0000-0002-6742-7223
Anna M PiskorskiDepartment of Pathology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Ali AminDepartment of Pathology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Chanika PhornphutkulDivision of Human Genetics, Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Suzanne de la MonteDepartment of Pathology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Thierry VilbouxOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Folami DuncanOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Joan PellegrinoMedical Genetics, Upstate Medical University, Syracuse, New York, USA.
Bonnie BraddockMedical Genetics, Upstate Medical University, Syracuse, New York, USA.
Lindsay A MiddeltonUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Laura S SchmidtUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Maria J MerinoLaboratory of Pathology Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Edward W CowenDermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA.
Wendy J IntroneOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Ann C M SmithOffice of the Clinical Director, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.ORCID 0000-0002-0729-9063
Brown University · USNational Cancer Institute · USNational Human Genome Research Institute · USSUNY Upstate Medical University · USFrederick National Laboratory for Cancer Research · USJohns Hopkins University · USNational Institute of Arthritis and Musculoskeletal and Skin Diseases · US

Funding

Human Biochemical GeneticsZIAHG000215 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI GAHL, WILLIAM · 2009 to 2025
$72.6M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Clinical Nursing and Data Management CoreZIDBC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.4M
Tissue ProcessingSequencing FacilityZICBC011044 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI VOCKE, CATHY D · 2009 to 2025
$13.5M
FASD Inhibition of ASPH-Notch Mediates Adolescent Cerebral White Matter Pathology-Potential Utility of Non-invasive Extracellular Vesicle AssaysR01AA011431 · NIAAA · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI SUZANNE M. DE LA MONTE · 1996 to 2026
$5.4M
Dermatology Consultation ServiceZIAAR041229 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI COWEN, EDWARD · 2022 to 2025
$4.0M
Ethanol, IRS-1 Signaling and Neuronal MigrationR37AA011431 · NIAAA · RHODE ISLAND HOSPITAL · PI DE LA MONTE, SUZANNE M. · 2009 to 2018
$3.7M
Pathogenesis of Early- Versus Late-Stage Alcohol-Mediated White Matter DegenerationR01AA028408 · NIAAA · RHODE ISLAND HOSPITAL · PI DE LA MONTE, SUZANNE M. · 2021 to 2025
$1.7M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAAA NIH HHS R01 AA011431NIAAA NIH HHS R01 AA028408NIAAA NIH HHS R37 AA011431
6 · The paper itself

Abstract

We report a series of four unrelated adults with Smith-Magenis syndrome (SMS) and concomitant features of Birt-Hogg-Dubé (BHD) syndrome based upon haploinsufficiency for FLCN and characteristic renal cell carcinomas and/or evidence of cutaneous fibrofolliculomas. Three of the cases constitute the first known association of histopathologically verified characteristic BHD-associated renal tumors in adults with SMS; the fourth was identified to have histologically confirmed skin fibrofolliculomas. Molecular analysis documented second-hit FLCN mutations in two of the three cases with confirmed BHD renal pathology. These cases suggest the need to expand management recommendations for SMS to include kidney cancer surveillance starting at 20 years of age, as per the screening recommendations for BHD syndrome.

Indexed as

Birt-Hogg-Dube SyndromeCarcinoma, Renal CellKidney NeoplasmsSkin NeoplasmsSmith-Magenis SyndromeAdultEarly Detection of CancerHumansProto-Oncogene ProteinsTumor Suppressor ProteinsProto-Oncogene ProteinsTumor Suppressor ProteinsBirt-Hogg-Dubé syndromecancer riskcancer surveillancedel 17p11.2FLCNSmith-Magenis syndrome

Identifiers

PMID36513625
PMCPMC10117402
OpenAlexW4311307322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.